XML Sitemap

This is a XML Sitemap which is supposed to be processed by search engines which follow the XML Sitemap standard like Ask.com, Bing, Google and Yahoo.
It was generated using the WordPress content management system and the Google Sitemap Generator Plugin by Arne Brachhold.
You can find more information about XML sitemaps on sitemaps.org and Google's list of sitemap programs.

URLPriorityChange frequencyLast modified (GMT)
https://xconomy.com/national/2019/12/24/allergan-wins-fda-nod-for-first-migraine-pill-in-new-class-of-medicines/60%Monthly2019-12-24 19:32
https://xconomy.com/national/2019/12/24/evotec-ceo-discusses-ways-to-make-drug-rd-faster-and-better/60%Monthly2019-12-23 22:21
https://xconomy.com/boston/2019/12/23/roche-puts-up-historic-1-15b-for-sarepta-duchenne-gene-therapy-deal/60%Monthly2020-05-29 13:39
https://xconomy.com/national/2019/12/23/healthcare-ai-tech-is-here-now-we-must-learn-to-manage-the-data/60%Monthly2020-05-28 20:15
https://xconomy.com/san-francisco/2019/12/20/encoded-makes-chief-regulatory-people-culture-officer-appointments/60%Monthly2019-12-21 01:16
https://xconomy.com/national/2019/12/20/bio-roundup-amarins-approval-ftc-v-illumina-a-120m-deal-more/60%Monthly2019-12-23 20:54
https://xconomy.com/san-diego/2019/12/19/biogen-strikes-alzheimers-deal-paying-45m-for-ionis-tau-drug-rights/60%Monthly2019-12-20 00:25
https://xconomy.com/new-york/2019/12/19/takeda-pays-turnstone-120m-to-start-alliance-on-viral-cancer-therapies/60%Monthly2019-12-20 19:52
https://xconomy.com/boston/2019/12/19/ring-therapeutics-launches-to-expand-gene-therapy-viral-vector-options/60%Monthly2020-05-29 13:39
https://xconomy.com/boulder-denver/2019/12/18/archerdx-raises-55m-to-help-physicians-pick-best-cancer-therapies/60%Monthly2019-12-19 18:08
https://xconomy.com/san-diego/2019/12/18/ftc-challenges-pacbio-acquisition-says-illumina-is-a-monopolist/60%Monthly2019-12-18 22:50
https://xconomy.com/boston/2019/12/18/zafgens-path-forward-is-reverse-merger-with-chondrial-therapeutics/60%Monthly2019-12-18 17:15
https://xconomy.com/national/2019/12/18/orbiting-organoids-research-in-space-to-unveil-new-neurodegeneration-insight/60%Monthly2020-05-29 13:34
https://xconomy.com/boston/2019/12/18/ipsens-meek-departs-for-ceo-role-at-gene-therapy-newco-fergene/60%Monthly2019-12-18 17:46
https://xconomy.com/boston/2019/12/17/nimbus-therapeutics-taps-annie-chen-to-lead-subsidiary/60%Monthly2019-12-17 23:27
https://xconomy.com/seattle/2019/12/17/palo-alto-health-names-dean-sawyer-president-ceo/60%Monthly2019-12-17 23:32
https://xconomy.com/europe/2019/12/17/als-fund-talks-investments-and-strategy-as-it-kicks-off-100m-campaign/60%Monthly2019-12-17 20:46
https://xconomy.com/boston/2019/12/17/triplet-therapeutics-unveils-59m-to-try-hairpin-fix-for-huntingtons/60%Monthly2019-12-17 04:11
https://xconomy.com/san-diego/2019/12/16/organovos-demise-offers-path-for-tarveda-to-join-the-public-markets/60%Monthly2019-12-17 04:29
https://xconomy.com/san-diego/2019/12/16/zentalis-pharma-names-melissa-epperly-as-its-chief-financial-officer/60%Monthly2019-12-17 00:06
https://xconomy.com/san-francisco/2019/12/16/grail-appoints-illuminas-gautam-kollu-as-chief-commercial-officer/60%Monthly2019-12-16 23:47
https://xconomy.com/boston/2019/12/16/wave-stock-crashes-after-decision-to-halt-duchenne-drug-studies/60%Monthly2019-12-16 18:38
https://xconomy.com/boston/2019/12/16/cell-reprograming-startup-bit-bio-inks-pact-with-charles-river/60%Monthly2020-05-29 13:28
https://xconomy.com/new-york/2019/12/16/axsomes-depression-drug-meets-phase-3-goals-fda-filing-planned/60%Monthly2019-12-16 15:41
https://xconomy.com/boston/2019/12/16/building-a-better-3d-bioprinter-ge-healthcare-and-asls-combine-tech/60%Monthly2019-12-16 14:11
https://xconomy.com/new-york/2019/12/13/amarins-fish-oil-pill-wins-fda-nod-to-cut-heart-attack-stroke-risk/60%Monthly2019-12-16 19:18
https://xconomy.com/boulder-denver/2019/12/13/miragen-promotes-diana-escolar-to-chief-medical-officer/60%Monthly2019-12-13 21:21
https://xconomy.com/san-francisco/2019/12/13/alector-appoints-suliman-president-chief-operating-officer/60%Monthly2019-12-13 21:01
https://xconomy.com/boston/2019/12/13/pyxis-oncology-names-sullivan-ceo-steinberg-remains-on-the-board/60%Monthly2019-12-13 20:56
https://xconomy.com/national/2019/12/13/bio-roundup-sareptas-approval-merck-ma-drug-price-bill-more/60%Monthly2019-12-13 14:52
https://xconomy.com/boston/2019/12/13/in-an-about-face-fda-approves-second-sarepta-muscular-dystrophy-drug/60%Monthly2019-12-13 12:38
https://xconomy.com/boulder-denver/2019/12/12/miragen-restructures-to-focus-on-fibrosis-inks-20m-stock-deal/60%Monthly2019-12-12 22:13
https://xconomy.com/national/2019/12/12/amgens-osteoporosis-drug-wins-european-nod-with-a-heart-warning/60%Monthly2019-12-12 18:27
https://xconomy.com/san-diego/2019/12/12/aspen-neuro-bags-6-5m-to-test-parkinsons-disease-stem-cell-therapy/60%Monthly2020-05-29 13:28
https://xconomy.com/san-diego/2019/12/11/prometheus-bio-taps-thierry-dervieux-as-chief-development-officer/60%Monthly2019-12-11 20:41
https://xconomy.com/san-diego/2019/12/11/locana-names-casebia-therapeuticss-jim-burns-as-new-ceo/60%Monthly2019-12-11 20:26
https://xconomy.com/national/2019/12/11/iterums-antibiotic-for-super-bugs-falls-short-in-phase-3-shares-sink/60%Monthly2019-12-17 19:01
https://xconomy.com/boston/2019/12/11/flagships-cellarity-aims-to-advance-cell-behavior-based-therapeutics/60%Monthly2019-12-11 19:23
https://xconomy.com/boston/2019/12/10/flexion-co-founder-chief-scientific-officer-neil-bodick-to-retire/60%Monthly2019-12-10 22:09
https://xconomy.com/boston/2019/12/10/replimune-taps-ex-merrimack-exec-for-chief-financial-officer-post/60%Monthly2019-12-10 22:03
https://xconomy.com/boston/2019/12/10/kalvista-pharma-eye-drug-partnered-with-merck-flunks-phase-2-test/60%Monthly2019-12-10 19:15
https://xconomy.com/national/2019/12/10/zentalis-steps-out-with-147m-raised-to-develop-tried-and-true-small-molecules/60%Monthly2019-12-10 13:46
https://xconomy.com/san-diego/2019/12/10/scripps-research-abbvie-expand-drug-discovery-deal-beyond-cancer/60%Monthly2019-12-10 12:25
https://xconomy.com/new-york/2019/12/10/perceptive-unveils-new-200m-fund-to-invest-in-early-stage-biotechs/60%Monthly2019-12-10 13:07
https://xconomy.com/san-diego/2019/12/09/eying-cancer-combos-sanofi-to-splash-out-2-5b-on-san-diegos-synthorx/60%Monthly2019-12-13 10:13
https://xconomy.com/national/2019/12/09/aurinia-plans-fda-filing-after-lupus-nephritis-drug-hits-phase-3-goals/60%Monthly2019-12-09 20:46
https://xconomy.com/new-york/2019/12/09/merck-makes-a-big-blood-cancer-bet-with-2-7b-deal-for-arqule/60%Monthly2019-12-10 20:23
https://xconomy.com/san-francisco/2019/12/09/bridgebio-pharma-onboards-eli-wallace-to-lead-oncology-programs/60%Monthly2019-12-09 13:28
https://xconomy.com/san-diego/2019/12/09/insitro-hires-serafim-batzoglou-as-its-first-chief-data-officer/60%Monthly2019-12-09 12:55
https://xconomy.com/boston/2019/12/09/astrazeneca-taps-gatehouse-bio-to-identify-potential-drug-targets/60%Monthly2019-12-09 12:35
https://xconomy.com/san-diego/2019/12/06/3-takeaways-from-the-resurrection-of-biogens-alzheimers-drug/60%Monthly2019-12-07 01:09
https://xconomy.com/raleigh-durham/2019/12/06/dukes-jacob-jacobsen-joins-evecxia-as-chief-scientific-officer/60%Monthly2019-12-06 22:41
https://xconomy.com/boston/2019/12/06/akcea-therapeutics-appoints-alex-howarth-chief-operating-officer/60%Monthly2019-12-06 23:15
https://xconomy.com/san-diego/2019/12/06/acadia-looks-to-expand-drug-beyond-parkinsons-disease-psychosis/60%Monthly2019-12-06 20:39
https://xconomy.com/national/2019/12/06/fda-puts-partial-hold-on-tests-of-ipsen-drug-acquired-in-1b-deal/60%Monthly2019-12-06 17:13
https://xconomy.com/national/2019/12/06/bio-roundup-biogen-at-ctad-sages-stumble-astellass-3b-offer-more/60%Monthly2019-12-06 19:45
https://xconomy.com/national/2019/12/05/biogen-points-to-enrollment-and-dosing-to-explain-alzheimers-results/60%Monthly2019-12-06 05:11
https://xconomy.com/boston/2019/12/05/fda-rejects-enzyvants-regenerative-therapy-for-rare-immune-disorder/60%Monthly2019-12-05 17:59
https://xconomy.com/boston/2019/12/05/sage-therapeutics-depression-drug-fails-in-phase-3-shares-fall-60/60%Monthly2019-12-05 17:01
https://xconomy.com/san-diego/2019/12/05/as-alzheimers-conference-kicks-off-all-eyes-are-on-biogens-drug/60%Monthly2019-12-05 22:38
https://xconomy.com/new-york/2019/12/04/6-experimental-alzheimers-disease-diagnostic-projects-get-funding-boost/60%Monthly2019-12-04 22:38
https://xconomy.com/san-francisco/2019/12/04/nektar-therapeutics-names-john-northcott-chief-commercial-officer/60%Monthly2019-12-04 21:54
https://xconomy.com/boston/2019/12/04/avrobios-gabriel-cohn-joins-homology-as-chief-medical-officer/60%Monthly2019-12-06 23:55
https://xconomy.com/boston/2019/12/04/civetta-therapeutics-unveils-a-propeller-protein-plan-53m-in-funding/60%Monthly2019-12-04 21:44
https://xconomy.com/national/2019/12/04/fda-green-lights-sight-diagnostics-finger-prick-blood-test/60%Monthly2019-12-04 17:06
https://xconomy.com/raleigh-durham/2019/12/04/digital-health-survivors-innovative-incumbents-must-team-up-for-true-disruption/60%Monthly2019-12-04 08:45
https://xconomy.com/san-francisco/2019/12/04/roche-notches-fda-nod-in-lung-cancer-amps-up-competition-with-merck/60%Monthly2019-12-04 15:53
https://xconomy.com/national/2019/12/04/gho-capital-raises-over-1bn-eyes-biotech-outsourcing-services/60%Monthly2019-12-04 20:37
https://xconomy.com/san-diego/2019/12/03/stemonix-atomwise-team-up-on-drug-discovery-with-microorgans-and-ai/60%Monthly2020-05-28 19:46
https://xconomy.com/san-francisco/2019/12/03/veracyte-aims-to-expand-diagnostics-reach-with-50m-nanostring-deal/60%Monthly2019-12-04 21:08
https://xconomy.com/boston/2019/12/03/repare-therapeutics-taps-clementia-pharmas-steve-forte-as-its-new-cfo/60%Monthly2019-12-03 20:00
https://xconomy.com/seattle/2019/12/03/partner-or-die-how-to-succeed-even-after-the-digital-health-hype-quiets-down/60%Monthly2019-12-04 19:28
https://xconomy.com/boston/2019/12/03/caraway-therapeutics-names-martin-williams-as-ceo/60%Monthly2019-12-04 19:21
https://xconomy.com/national/2019/12/03/a-safer-crispr-cyrus-broad-institute-look-to-quell-concerns/60%Monthly2020-05-29 13:39
https://xconomy.com/national/2019/12/03/astellas-bets-on-gene-therapy-with-3b-audentes-acquisition-offer/60%Monthly2020-05-29 13:41
https://xconomy.com/san-diego/2019/12/02/neurocrine-inks-50m-xenon-pharma-deal-to-expand-into-epilepsy/60%Monthly2020-01-17 03:58
https://xconomy.com/san-francisco/2019/12/02/curtis-ruegg-to-succeed-amphivena-founder-as-new-ceo-president/60%Monthly2019-12-02 19:26
https://xconomy.com/boston/2019/12/02/ifms-glick-becomes-executive-chairman-seidel-promoted-to-ceo/60%Monthly2019-12-02 18:00
https://xconomy.com/boston/2019/12/02/agenus-chief-technology-officer-alex-duncan-to-depart-in-january/60%Monthly2019-12-02 17:55
https://xconomy.com/boston/2019/12/02/ifm-lands-55-5m-to-launch-newco-quattro-and-discovery-incubator/60%Monthly2019-12-02 13:59
https://xconomy.com/national/2019/12/02/deep-6-ai-adds-17m-to-advance-clinical-trial-recruitment-software/60%Monthly2019-12-02 12:49